3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
23
Burkitt Lymphoma
14
Sarcoma
13
Neoplasms
11
Lymphoma, Follicular
11
Lymphoma
10
Hodgkin Disease
9
Breast Neoplasms
9
Triple Negative Breast Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, Non-Hodgkin
8
Endometrial Neoplasms
8
Ovarian Neoplasms
7
Lymphoma, B-Cell
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
5
Wilms Tumor
4
Recurrence
4
Osteosarcoma
4
Neoplasm Metastasis
4
Liposarcoma
4
Fallopian Tube Neoplasms
4
Sarcoma, Ewing
3
Neuroblastoma
3
Lymphoproliferative Disorders
3
Lymphoma, T-Cell
3
Lymphoma, Mantle-Cell
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia, Biphenotypic, Acute
3
Leiomyosarcoma
3
Interventions
Cyclophosphamide
5
ibrutinib
4
fludarabine
4
pirtobrutinib
3
obinutuzumab
3
acalabrutinib
3
fludarabine phosphate
2
Rituximab
2
Mesna
2
venetoclax
1
ricolinostat
1
idelalisib
1
Whole-Body Irradiation
1
Vincristine
1
Tacrolimus
1
Stem Cell Transplantation
1
Prednisone
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Mycophenolic Acid
1
Melphalan
1
Leukapheresis
1
Doxorubicin
1
Diet
1
Busulfan
1
Bone Marrow Transplantation
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, B-Cell
×
Doxorubicin
×
90 days
×
Clear all
NCT06564038
2026-05-14
Soundtrack-E
AstraZeneca
Phase 1/2
Recruiting
408 enrolled